Actively Recruiting
Phase 2a Trial Evaluating Safety and Immune Response of MTBVAC Compared to BCG in Adolescents and Adults With and Without HIV
Led by HIV Vaccine Trials Network · Updated on 2026-10-30
276
Participants Needed
16
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and immune response of the MTBVAC vaccine in adolescents and adults aged 12 to 55 years, both living with and without HIV in South Africa. This Phase 2a clinical trial aims to compare MTBVAC with the BCG vaccine in participants grouped based on their HIV status, CD4 T cell count, and interferon-gamma release assay IGRA status. The study is conducted by the HIV Vaccine Trials Network and involves randomized assignment without a placebo group. Participants will receive a single intradermal injection of either MTBVAC or BCG vaccine, each at a volume of 0.1 mL, administered in the upper arm at the start of the study. The study is divided into two parts and three cohorts, with enrollment proceeding sequentially based on safety criteria. Follow-up will continue for 48 weeks after vaccination to monitor safety and immune responses. During the study, participants will undergo various assessments including monitoring for adverse events up to 48 weeks, measurement of specific immune cell responses at baseline and multiple time points, gene expression profiling, and antibody levels. Researchers will also evaluate the acceptability of the vaccines. Safety monitoring includes tracking serious and solicited adverse events, with a focus on immune markers such as CD4 and CD8 T cells expressing certain cytokines. Participants will be asked to attend scheduled visits for these assessments throughout the study period.
CONDITIONS
Brief Title
Evaluating the Safety and Immunogenicity of MTBVAC
Research Team
K
Kylie McCloskey
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here